SEC Form 4 · accession 0000884731-16-000039
ARIAD PHARMACEUTICALS INC · ARIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy P Clackson
Officer — President, R&D, CSO
Period of report
Apr 29, 2016
Accepted (ET)
May 2, 2016 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000884731
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 29, 2016 | M | 23,400 | $0.00 | A | 318,203 | D | |
| Common StockF3 | May 2, 2016 | S | 11,700 | $7.1349 | D | 306,503 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F5 | $0.00 | Apr 29, 2016 | M | 23,400 | D | — | — | Common Stock | 23,400 | 0 | D |
Explanation of responses
- F1shares were acquired upon the vesting of an RSU granted April 29, 2015
- F2Represents shares sold to satisfy withholding tax requirements pursuant to a Rule 10b5-1 trading plan.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.02 to $7.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer,or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- F4Restricted stock units vest as to 33-1/3% of the award on each of April 29, 2016, April 29, 2017 and April 29, 2018.
- F5N/A